Press release

[PRESS RELEASE] SIGHT DIAGNOSTICS RAISES $71M TO ACCELERATE GLOBAL EXPANSION OF ITSFDA 510(K) CLEARED, CE MARKED FINGER-PRICK BLOOD ANALYZER

[PRESS RELEASE] SIGHT DIAGNOSTICS RAISES $71M TO ACCELERATE GLOBAL EXPANSION OF ITSFDA 510(K) CLEARED, CE MARKED FINGER-PRICK BLOOD ANALYZER

Aug 7, 2020 |

Tel Aviv, Israel (August 5, 2020) – Sight Diagnostics, the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, announced today it has raised $71 million in Series D funding with participation from Koch Disruptive Technologies, Longliv Ventures and OurCrowd. This new round brings Sight’s total funding to more than $124 million and will support the expansion of Sight’s commercial operations globally and advance Sight’s R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity. Read more...

Read More
PRESS RELEASE: Sight Diagnostics Raises $71M To Accelerate Global Expansion of itsFDA 510(k) Cleared, CE Marked Finger-prick Blood Analyzer

PRESS RELEASE: Sight Diagnostics Raises $71M To Accelerate Global Expansion of itsFDA 510(k) Cleared, CE Marked Finger-prick Blood Analyzer

Aug 6, 2020 |

Sight Diagnostics Raises $71M To Accelerate Global Expansion of its FDA 510(k) Cleared, CE Marked Finger-prick Blood Analyzer The investment from Koch Disruptive Technologies, Longliv Ventures, a member of the CK Hutchison Holdings and OurCrowd will fuel Sight’s R&D into the automated identification and detection of diseases Tel Aviv, Israel (August 5, 2020) – Sight DiagnosticsⓇ, the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, announced today it has raised $71 million in Series D funding with participation from Koch Disruptive Technologies, Longliv Ventures and OurCrowd. This new round brings Sight’s total funding to more than $124 million and will support the expansion of Sight’s commercial operations globally and advance Sight’s R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity. “We firmly believe that Sight’s method of using machine vision to analyze blood is a significant leap forward from the current alternative in healthcare,” said Chase Koch, President of Koch Disruptive Technologies. “Not only is the company bringing truly innovative solutions to the blood diagnostics industry, it is also driving a...

Read More
[PRESS RELEASE] Thousands of investors from 90 countries attend OurCrowd Pandemic Innovation Conference online, first global event dedicated to pandemic investment

[PRESS RELEASE] Thousands of investors from 90 countries attend OurCrowd Pandemic Innovation Conference online, first global event dedicated to pandemic investment

Jun 22, 2020 |

JERUSALEM, JUNE 22, 2020 – OurCrowd, the world’s largest global venture investing platform, today hosted the OurCrowd Pandemic Innovation Conference, a live interactive event, which brought together thousands of top investors, entrepreneurs, venture capitalists, corporate executives, government officials and press from over 90 countries around the world. Read more...

Read More